- Home
- ACAD vs SIM Comparison
ACAD vs SIM Comparison
Compare ACAD & SIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- SIM
- Stock Information
- Founded
- ACAD 1993
- SIM 1969
- Country
- ACAD United States
- SIM Mexico
- Employees
- ACAD N/A
- SIM N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- SIM Steel/Iron Ore
- Sector
- ACAD Health Care
- SIM Industrials
- Exchange
- ACAD Nasdaq
- SIM Nasdaq
- Market Cap
- ACAD 4.3B
- SIM 4.3B
- IPO Year
- ACAD 2004
- SIM 1993
- Fundamental
- Price
- ACAD $24.67
- SIM $28.06
- Analyst Decision
- ACAD Buy
- SIM
- Analyst Count
- ACAD 21
- SIM 0
- Target Price
- ACAD $29.30
- SIM N/A
- AVG Volume (30 Days)
- ACAD 1.8M
- SIM 206.0
- Earning Date
- ACAD 11-05-2025
- SIM 10-30-2025
- Dividend Yield
- ACAD N/A
- SIM N/A
- EPS Growth
- ACAD 615.00
- SIM N/A
- EPS
- ACAD 1.33
- SIM 1.84
- Revenue
- ACAD $1,018,885,000.00
- SIM $1,708,192,766.00
- Revenue This Year
- ACAD $14.01
- SIM N/A
- Revenue Next Year
- ACAD $11.72
- SIM N/A
- P/E Ratio
- ACAD $18.55
- SIM $15.21
- Revenue Growth
- ACAD 14.41
- SIM N/A
- 52 Week Low
- ACAD $13.40
- SIM $22.15
- 52 Week High
- ACAD $26.65
- SIM $31.00
- Technical
- Relative Strength Index (RSI)
- ACAD 49.69
- SIM 56.05
- Support Level
- ACAD $23.34
- SIM $26.76
- Resistance Level
- ACAD $25.90
- SIM $28.00
- Average True Range (ATR)
- ACAD 0.78
- SIM 0.00
- MACD
- ACAD -0.28
- SIM -0.04
- Stochastic Oscillator
- ACAD 40.18
- SIM 100.00
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About SIM Grupo Simec S.A.B. de C.V.
Grupo Simec SAB de CV is a diversified producer, processor and distributor of SBQ steel and structural steel products with production and commercial operations. The group's SBQ products are used across a range of engineered end-user applications, including axles, hubs, and crankshafts for automobiles and light trucks, machine tools, and off-highway equipment. Its structural steel products are used in the non-residential construction market and other construction applications. Its segments are Mexico, Brazil, and the United States. The maximum of its sales is from the Mexico segment.